Disease · MONDO_0005173

actinic keratosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. actinic keratosis. Diseases, record MONDO_0005173. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005173

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: actinic keratosis; Open Targets
Open Targets ID: MONDO_0005173; Open Targets
Other names: SK - Solar keratosis, Senile hyperkeratosis, actinic (solar) keratosis, actinic keratosis (disease), actinic keratosis (disorder), actinic keratosis (morphologic abnormality), solar keratosis; Open Targets
Disease Ontology: DOID:8866; Disease Ontology
MeSH: D055623; MeSH
NCI Thesaurus: C3148; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 32 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INGENOL MEBUTATE	CHEMBL1863513	Small molecule	Approval	DailyMed and TTD	42	39	39	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Approval	DailyMed and EMA Human Drugs	27	23	23	Drugs and targets
AMINOLEVULINIC ACID	CHEMBL601	Small molecule	Approval	TTD	20	19	16	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	DailyMed	15	14	14	Drugs and targets
TIRBANIBULIN	CHEMBL571546	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA and TTD	17	12	12	Drugs and targets
AMINOLEVULINIC ACID HYDROCHLORIDE	CHEMBL1200582	Small molecule	Approval	EMA Human Drugs and TTD	11	9	6	Drugs and targets
METHYL AMINOLEVULINATE	CHEMBL1096562	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
INGENOL DISOXATE	CHEMBL3989918	Small molecule	Phase 3	ClinicalTrials.gov	11	10	10	Drugs and targets
DICLOFENAC SODIUM	CHEMBL1034	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CALCIPOTRIENE	CHEMBL1200666	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
TLR7	Toll-like receptor 7	2	Toll-like receptor 7 agonist	Approval	https://conductscience.org/library/genes/51284	Drugs and targets
ATP1A1	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/476	Drugs and targets
ATP1A2	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/477	Drugs and targets
ATP1A3	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/478	Drugs and targets
ATP1A4	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/480	Drugs and targets
ATP1B1	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/481	Drugs and targets
ATP1B2	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/482	Drugs and targets
ATP1B3	Sodium/potassium-transporting ATPase	1	Sodium/potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/483	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials149

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02361216	Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest	Phase 3	729	2018-10-03	Actinic Keratosis	INGENOL MEBUTATE	Its record names the disease	ClinicalTrials.gov
NCT02952898	Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses	Phase 3	665	2019-01-10	Actinic Keratosis	DICLOFENAC SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01686152	Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis	Phase 3	589	2020-10-30	Actinic Keratosis	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT02799069	Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy	Phase 3	571	2017-03-23	Actinic Keratosis	AMINOLEVULINIC ACID HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04085367	Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face	Phase 3	557	2022-04-01	Actinic Keratoses	METHYL AMINOLEVULINATE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00116649	Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis	Phase 4	551	2008-11-25	Keratosis	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT02385318	To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis	Phase 3	519	2021-01-22	Actinic Keratosis	INGENOL MEBUTATE	Its record names the disease	ClinicalTrials.gov
NCT03200912	An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis	Phase 3	507	2020-01-14	ACTINIC KERATOSIS	INGENOL MEBUTATE	Its record names the disease	ClinicalTrials.gov
NCT00603798	Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)	Phase 3	490	2010-06-22	Actinic Keratosis	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT01926496	Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%	Phase 4	485	2020-07-29	Actinic Keratosis (AK)	IMIQUIMOD, INGENOL MEBUTATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 149

See all 149 trials

Comparisons in its trials74

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ingenol Mebutate Gel vs Vehicle: deaths from any cause	0 of 549	0 of 176	725	NCT02361216	Trial comparisons
Ingenol Mebutate Gel vs Vehicle: serious adverse events	8 of 549	2 of 176	725	NCT02361216	Trial comparisons
MAL 16.8% Cream vs MAL Vehicle Cream: deaths from any cause	0 of 364	0 of 193	557	NCT04085367	Trial comparisons
MAL 16.8% Cream vs MAL Vehicle Cream: serious adverse events	5 of 364	1 of 193	557	NCT04085367	Trial comparisons
Ingenol Mebutate vs Imiquimod: Number of Participants With Complete Clearance of AK Lesions After Last Treatment	168 of 240	192 of 245	485	NCT01926496	Trial comparisons
Ingenol Mebutate vs Imiquimod: Number of Participants With Complete Clearance of AK Lesions at 12 Months	70 of 240	108 of 245	485	NCT01926496	Trial comparisons
Ingenol Mebutate vs Imiquimod: Number of Participants With Partial Clearance of AK Lesions	195 of 240	210 of 245	485	NCT01926496	Trial comparisons
KX2-391 Ointment 1% vs Placebo: Number of Participants With Clinically Significant Safety Observations- Physical Examination	0 of 175	0 of 176	351	NCT03285477	Trial comparisons
KX2-391 Ointment 1% vs Placebo: Number of Participants With Clinically Significant Safety Observations- Vital Signs	0 of 175	0 of 176	351	NCT03285477	Trial comparisons
KX2-391 Ointment 1% vs Placebo: deaths from any cause	0 of 175	1 of 176	351	NCT03285477	Trial comparisons

1 to 10 of 74

See all 74 comparisons in its trials

Papers from its trials50

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34743007	RESULT	1	PubMed
31955461	RESULT	1	PubMed
24892649	RESULT	1	PubMed
23553119	RESULT	4	PubMed
23510990	RESULT	1	PubMed
23252768	RESULT	1	PubMed
22714759	RESULT	1	PubMed
22417254	RESULT	5	PubMed
22055282	RESULT	1	PubMed
21753882	RESULT	1	PubMed

1 to 10 of 50

See all 50 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005173

GET https://conductscience.org/api/diseases/v1/MONDO_0005173/drugs?page=2

API reference For AI assistants